Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood FlowCaroline J. Breitbach, John C. Bell, David F. Stojdl et al.|Molecular Therapy|2007Cited by 277
Harnessing Oncolytic Virus-mediated Antitumor Immunity in an Infected Cell VaccineChantal G. Lemay, Rebecca C. Auer, Julia L. Rintoul et al.|Molecular Therapy|2012Cited by 93
Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus MacaquesLaura Evgin, J. Andrea McCart, Sergio A. Acuña et al.|Molecular Therapy|2015Cited by 80
ORFV: A Novel Oncolytic and Immune Stimulating Parapoxvirus TherapeuticJulia L. Rintoul, John C. Bell, Chantal G. Lemay et al.|Molecular Therapy|2012Cited by 71
Model-based rational design of an oncolytic virus with improved therapeutic potentialFabrice Le Bœuf, John C. Bell, Cory Batenchuk et al.|Nature Communications|2013Cited by 44